Cursos

Actividades Académicas
Atrás

New complications of the diabetic syndrome in the new millenium: Type 3 Diabetes?

Información General

Programa curso

programa

Tríptico imprenta

programa definitivo

Becarios

Listado resolución becas

Matrícula

Procedimiento matricula on-line
Código
630B
Horas
12
Fecha
07 Sep 2016
09 Sep 2016
Precio
130 € Tarifa A
Tipo
Encuentro
Temática
Medicina y Ciencias de la Salud
ECTS
0,5

Sede donde se gestiona

Santander

Lugar de impartición

Santander - Península de la Magdalena (Infantes)

Dirección

Manuel Benito
PhD. DPhil. Complutense University & CIBERDEM (ISCIII)
Madrid, Spain


PATROCINIO

Alianza Boehringer-Lilly

AstraZeneca Farmacéutica Spain, S.A.

Descripción de la actividad

Type 2 diabetes together with the metabolic syndrome much affect the human health worldwide: 30% global epidemics. In 1931, Elliot P. Joslin wrote: “It is time to move on from diabetes coma to diabetes complications”. Indeed, in 1999 AHA recognized diabetes as a cardiovascular disease. However, new threatening have emerged over the latest years. Thus, more that 50% of the deceased patients affected with the Alzheimer disease showed glycosylated proteins in their necropsies in hippocampal and non-hippocampal brain structures. Thus, a new concept of Diabetes, type 3 Diabetes?, is currently on going. Indeed, the underlying molecular mechanism of such epidemiological association it is almost unknown. On the other hand, patients undergoing a long-standing insulin treatment of their type 1 diabetes showed hyperplastic focus in their retinas, suggesting a hyperproliferative side effect by the chronic insulin treatment. Indeed, insulin resistance it is the earliest pathophysiological event of type 2 diabetes, wich it is associated to for a long while to a compensatory hyperinsulinemia. In 2010, a consensus was reached associating the hyperinsulinemia of the prediabetes or type 2 diabetic patients to an enhanced susceptibility to develop a gastrointestinal tumor.

Participantes

DIRECCIÓN

Manuel Benito
PhD. DPhil. Complutense University & CIBERDEM (ISCIII)
Madrid, Spain

PARTICIPANTES

Jesús Ávila
Associate Professor Ad Honorem CBMSO
(CSIC-UAM)& CIBERNED (ISCIII)
Madrid,Spain

Jesús Egido
Professor and Chairman, Department of Medicine, Autonoma University
Chief, Division of Nephrology and Hypertension
Director Renal, Vascular and Diabetes Research Lab. University Hospital
Fundación Jimenez Diaz & CIBERDEM (ISCIII)
Madrid, Spain

Emily Gallagher
Assistant Professor of Medicine and Endocrinology
Division of Diabetes, Endocrinology and Bone Diseases,
Department of Medicine. Mount Sinai School of Medicine
New York, USA

Holger J. Gellermann
Dr. Medical Director
Boehringer Ingelheim Spain

CR Kahn
Chief Academic Officer, Joslin Diabetes Center
Mary K. Iacocca Professor, Harvard Medical School. Boston, U.S.A.

Anna Krook
Professor.Department of Physiology and Pharmacology
Karolinska Institute
Stockholm, Sweden

Lorenzo Pasquali
MD, PhD Germans Trias i Pujol Research Institute

Cristina Rondinone
Vicepresident R&D
Head Cardiometabolic Diseases iMED
Medimmune/Astra-Zeneca
USA

Rafael Simó Canonge
Head of Diabetes and Metabolism Research Unit
Vall d'Hebron Research Institute
Barcelona & CIBERDEM (ISCIII),
Madrid, Spain

Ulf Smith
MD, PhD. Professor of Medicine
University of Gothenburg
Sweden

Programa

Miércoles, 7 Septiembre 2016

15:30
Opening remarks
A. Insulin resistance as the initial pathophysiological feature in type 2
15:45
Multiple Roles and Mechanisms Underlying Insulin Resistance in the Metabolic Syndrome
CR Kahn
The adipose organ: A source of insulin resistant signals
Ulf Smith
Skeletal muscle insulin sensitivity
Anna Krook

Jueves, 8 Septiembre 2016

B. Elastoplasticity of pancreatic endocrine cells: The tipe 2 diabetes progression
10:00
Molecular basis and regulatory networks of the pancreatic beta cell fate
Lorenzo Pasquali
Failure of the compensatory mechanisms of beta-cell insulin secretion: The crossroad of Autophaty/Apoptosis
Manuel Benito
12:00
Concluding remarks and Discussion
C. Type 2 diabetes and metabolic syndrome vascular complications
15:00
Type 2 diabetes, metabolic syndrome and macrovascular complications
Cristina Rondinone
Diabeteic nephropathy
Jesús Egido
Neurodegeneration in diabetic retinopathy: Therapeutic implications
Rafael Simó Canonge
18:00
Concluding remarks and Discussion

Viernes, 9 Septiembre 2016

D. Neurodegeneration and type 2 diabetes: Type 3 Diabetes?
09:00
Molecular basis of neurodegneration in the Alzheimer disease: The metabolic environment
Jesús Ávila
E. Cancer susceptibility associated to insulin resistance and type 2 diabetes
10:00
Type 2 diabetes, metabolic syndrome and cancer: The IGFI and insulin connection
Emily Gallagher
11:00
Concluding remarks and Discussion
F. Drugs Discovery: New therapeutics approaches
11:15
Beyond glucose control: addressing diabetes associated comorbidities
Holger J. Gellermann
12:15
Closure remarks